Findings showed treatment with lorundrostat resulted in statistically significant reductions in systolic blood pressure compared with placebo. Topline data were announced from a phase 3 trial ...

Amiloride is noninferior to spironolactone in lowering home systolic blood pressure over 12 weeks in patients with resistant hypertension. The finding is from the SPironolactone Versus Amiloride for ...

Lorundrostat (Mineralys Therapeutics), a novel aldosterone synthase inhibitor, can substantially lower blood pressure in patients with uncontrolled and treatment-resistant hypertension, according to ...

Idorsia receives approval from Health Canada for JERAYGO ™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension. JERAYGO is a new oral ...

TRYVIO (aprocitentan) in the US and JERAYGO in Europe present significant market potential as novel therapies for patients with hypertension inadequately controlled by existing treatments. TRYVIO, ...

A new drug has shown unprecedented promise in lowering blood pressure and preventing the progression of kidney disease for people with hard-to-treat hypertension. The medication, baxdrostat, reduces ...

A highly selective aldosterone synthase inhibitor, lorundrostat, showed promise for blood pressure reduction in a double-blind randomized phase IIb trial. Participants with uncontrolled and otherwise ...

In a country where nearly 1 in 3 adults silently battles high blood pressure , the need for regular blood pressure monitoring has never been more urgent. It's not just about early detection what ...

Resistant hypertension is a serious form of high blood pressure that persists despite the use of at least three antihypertensive medications from different classes, including a diuretic. In a recent ...